Moderna forecasts weaker sales as COVID vaccine demand wanes - National
Moderna said on Thursday its 2023 sales would only hit the low end of its previous forecast, reflecting weaker demand for COVID-19 vaccines.
Source: globalnews.ca
Stay updated with breaking news from Oderna Earnings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Moderna said on Thursday its 2023 sales would only hit the low end of its previous forecast, reflecting weaker demand for COVID-19 vaccines.
Covid vaccine maker Moderna, Inc. (MRNA) reported Thursday that its first-quarter net income plunged to $79 million from last year's $3.66 billion. Earnings per share were $0.